诺维本联合顺铂治疗老年非小细胞肺癌疗效观察

目的:观察诺维本(NVB)与顺铂(DDP)联合治疗老年非小细胞肺癌(NSCLC)的疗效和毒副反应.方法:老年组NSCLC 32例,予以NVB 25mg/m2于第1、8天静脉泵入,DDP 80mg/m2d1～3静滴,21天为一周期,至少化疗两周期,并与30例青年组NSCLC患者进行对比;按WHO疗效及毒副反应标准进行评价.结果:老年组中完全缓解(CR)1例(3.2%),部分缓解(PR)14例(43.7%),总有效率RR(CR PR)达46.9%,青年组中CR 1例(3.3%),PR 13例(43.3%),RR达46.6%,两组间差异无显著性(P＞0.05);中位生存期(MST)老年组和青年组分别为8.5个月和9.1个月,中位缓解时间(DRT)两组分别为4.5个月及4.0个月,两组间差异无显著性(P＞0.05);主要毒副作用为骨髓抑制、胃肠道反应和静脉炎.结论:NVB联合DDP对老年NSCLC的治疗有一定的客观缓解率,毒副反应低,耐受性好,值得临床推广.

CLINICAL STUDY OF VINORELBINE COMBINED WITH CISPLATIN IN THE TREATMENT OF ELDERLY PATIENTS WITH NON-SMALL-CELL LUNG CANCER

Objective:To evaluate the effective and toxicity of Vinorelbine(NVB) plus Cispiatin(DDP) in the treatment of elderly patients with non-small-cell lung cancer(NSCLC).Methods: 32 elderly patients with NSCLC were treated with NVB 25mg/m~2 iv drip for day 1?day 8 and DDP 80 mg/m~2 IVD for day 1~3.The second treatment cycle was given on day 22.And compared with 30 cases of young peoples with NSCLC.The objective effect was estimated according to the standard of WHO and the clinical benefit response was evaluated at the same time.Results: One patient had a complete response(CR),14 patients had a partial responses(PR),for overall response rate of 46.9% for the elderly patients and 46.6% for the young patients.There was no significance for overall response rate(P>0.05).The median survival time(MST) of elderly patients and young patients was 8.5 months and 9.1months;the diseases median response time(DRT) was 4.5 months and 4.0 month of it.MTS and DRT were similar in two groups(P>0.05).The main toxicities were seen bone marrow depression?gastro enteric tract reaction and phlebitis.Conclusion: NVB combined with DDP is effective and well tolerable for elderly patients with NSCLC.